Patrys (ASX:PAB)
Patrys’s Deoxymab 3E10 antibody, developed at Yale, prevents cancer cells from self-repairing their DNA when it breaks. Patrys has now upgraded this antibody for human use and has generated encouraging in vivo data across a range of cancers.
19/12/2017 Cell-penetrating monoclonal antibodies
03/05/2018 Favourable data continues to accrue